Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer diagnosed by biopsy, not appearance. Definition.
- A painless, growing lump can still need assessment.
- Coordinate skin and lymph-node assessment before treatment.
- A drug’s approval does not establish independent efficacy.
- Report new treatment symptoms promptly.
Table of contents
- Evidence summary
- Symptoms and diagnosis
- Virus, UV and spread
- Local and advanced care
- Nutrition, skin protection and supplements
- What the reviewed evidence establishes
- Side effects and urgent assessment
- Medicines, supplements and immune conditions
- Transplants, pregnancy and individual suitability
- Recovery and follow-up
- Animal and laboratory evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Diagnosis | Biopsy | Connected synthesis | Appearance cannot confirm MCC. |
| Care pathways | Guideline/PDQ | Connected provenance | Individual decisions. |
| Retifanlimab status | US 2025; UK 2026 decisions | Regulators receive industry fees | Jurisdictions and dates differ. |
| Independent efficacy | Sponsor protocol and disclosures | Manufacturer support documented | No cleared drug ranking adopted. |
| Supportive care | Public clinical education | Page/trial allocations unclosed | Safety context; no MCC efficacy inference. |
Symptoms and diagnosis
Growing, firm, painless red/pink/violet lumps need assessment; mimics exist.
Pathology panels exclude mimics, including lung small-cell metastases; no stain is infallible.
The April 2026 CAP protocol records tumor extent, margins, regional nodes and optional viral testing. It uses AJCC 8 staging; its accreditation requirement begins January 2027. Reporting standard.
Virus, UV and spread
MCC forms on or just beneath the skin, often in sun-exposed areas. It is more common in older people and those with weakened immunity. This risk context does not let a person rule cancer in or out from age, location or immune status. Risk context.
MCC has viral/UV pathways; healthy-skin polyomavirus cannot diagnose it. Cell origin remains uncertain.
Regional nodes and distant spread differ. MCC can present without an identifiable skin primary. Disease extent.
Stages I–II: localized; III: regional; IV: distant. Clinical/pathological findings matter. Staging.
A sentinel node is an early draining node. Biopsy removes and examines it for tumor. False-negative results are possible. Node assessment.
Local and advanced care
Localized/regional care may combine excision, node treatment and radiation; advanced/unresectable disease has systemic options, including checkpoint immunotherapy. Care pathways.
Assess frailty/operability. Clinically node-negative and fit for radical therapy: coordinate sentinel-node biopsy/excision. Adjuvant chemotherapy is not routine.
External-beam radiation directs treatment from a machine toward a defined area. Planning considers tumor location, nearby healthy structures, other treatments and whether the goal is control or symptom relief. Radiation context.
Chemotherapy acts on dividing cells and can also damage healthy tissues. Its side effects do not tell you whether it is working; the team assesses response using examinations and appropriate tests. Chemotherapy context.
The FDA converted retifanlimab’s MCC indication to traditional approval on 17 December 2025. The earlier accelerated status is historical. US decision.
On 6 July 2026, the MHRA authorized first-line retifanlimab for adults with metastatic or recurrent MCC not curable by surgery or radiation. This is a UK decision. UK decision.
Nutrition, skin protection and supplements
Treatment can reduce appetite or change how food is tolerated. Report weight loss and eating difficulties; a registered dietitian can tailor energy, protein and support to the treatment and your circumstances. Restrictive anticancer diets can complicate adequate intake. Keep the team informed about what you can actually eat and drink, rather than assuming every person needs the same calorie target or supplement. Nutrition support depends on symptoms, nutritional status and treatment goals. Nutrition support.
Reduce ultraviolet exposure with shade, protective clothing and sunscreen, and avoid tanning. Protection remains relevant across skin tones; it does not remove an established tumor or replace assessment of a changing lesion. UV protection.
Do not delay or replace care: black salves harm healthy tissue; antioxidants may interfere. Natural origin does not establish benefit or safety.
No supplement earns an independent MCC-treatment recommendation in this review. That is an evidence-screen conclusion, rather than proof that every imaginable product has been tested.
What the reviewed evidence establishes
Guidance provides context. Independent drug comparisons remain unverified; sponsored outcomes are excluded.
The retained POD1UM-201 protocol names Incyte as sponsor. Its disclosure requirements and sponsor publication-review provisions do not reveal every investigator’s receipts. We use it for funding identification, not an independent response or survival claim. Sponsor record.
Clinical trials ask research questions, including new treatment approaches and supportive care. A trial listing is not proof that an intervention is established or suitable for you. Research context.
If considering a study, ask about the protocol, sponsor, eligibility, alternatives and responsibility for care or costs. These are review prompts, not a promised benefit or recommendation to enroll.
Side effects and urgent assessment
Excision and node surgery can cause pain, bleeding, infection, damage to nearby tissues and anesthesia reactions. Follow the team’s wound and activity instructions; report uncontrolled pain or suspected infection. Surgical risks.
Radiation effects depend on the treatment field and can include fatigue and skin changes. Some effects emerge months or years later; ask which late problems apply to the actual field treated. Radiation risks.
Immunotherapy reactions can arise during treatment or after it ends. Severity cannot be predicted from how well you initially feel; maintain the team’s reporting plan. Skin or infusion-site reactions, fatigue, fever and diarrhea can occur, but symptoms alone cannot identify their cause. Report changes rather than deciding a reaction is harmless because someone else experienced it. Delayed reactions.
Checkpoint inflammation can affect bowel, lungs, liver, hormones, kidneys, heart or nerves. Diarrhea, black/bloody stool, cough, breathlessness, jaundice or unusual weakness needs prompt oncology assessment. Follow urgent instructions; keep medicine/contact details available for emergencies.
Fever of 38°C or higher, chills or other infection signs during cancer treatment need immediate contact with the oncology team. Ask before taking fever-reducing medicines, which can mask a serious problem. Infection urgency.
Sudden confusion, blue/pale/blotchy skin or very fast breathing can signal severe infection. Get immediate emergency help; do not wait for every sign to appear. Emergency advice.
Severe difficulty breathing, inability to get words out, a heavy/tight chest, blue-grey lips or sudden confusion requires immediate emergency help. Do not drive yourself. Breathing emergency.
UK emergency sources use 999/A&E; elsewhere use the local emergency service. Bringing treatment details is helpful, but must not delay care.
Medicines, supplements and immune conditions
Give the oncology pharmacist a complete list of prescription medicines, nonprescription products, vitamins and herbs. Some complementary products interfere with cancer treatment; natural origin or retail availability does not establish compatibility. Interaction assessment.
Disclose autoimmune disease before checkpoint treatment. The decision must consider inflammation risk and its management; this is not a reason to stop existing medicines yourself. Immune-condition review.
Before surgery, radiation or infusion, obtain a written medicine plan identifying the prescriber. Avoid self-directed changes.
Transplants, pregnancy and individual suitability
Retifanlimab can cause transplanted-organ rejection, serious allogeneic stem-cell transplant complications and fetal harm. Discuss pregnancy/contraception. Avoid breastfeeding during treatment and for four months afterward; pediatric safety/efficacy is unestablished.
These are product-specific restrictions; confirm the relevant treatment plan with the appropriate specialist.
Discuss goals, burdens, alternatives.
Recovery and follow-up
Follow preoperative testing, fasting and wound instructions, plus postoperative activity, pain and infection plans. Online advice cannot replace them. Recovery depends on the operation, anesthesia and usual activities; discuss return to work.
Use the oncology team’s instructions for treatment-field skin care. Radiation can cause peeling or moist wounds; immunotherapy can cause serious blistering or extensive rash. Report severe changes promptly rather than applying unapproved products. Skin care.
New limb heaviness or swelling after node treatment needs assessment, including other causes such as a clot. Fever with warm, red, painful swelling needs immediate clinical contact for possible cellulitis. Compression or drainage should follow a trained professional’s assessment. Swelling can emerge after treatment has ended; ask who will assess it and whether a certified lymphedema therapist is available. Swelling care.
Skin/scar/node follow-up, risk-tailored imaging; optimal surveillance lacks trial evidence, antibody monitoring nonuniversal.
Keep a treatment summary and an individual follow-up plan. Clarify who arranges tests, reviews results and coordinates ongoing problems with primary care; do not assume a new symptom should wait for a routine appointment. Care coordination.
Palliative care can accompany cancer-directed treatment at any stage. It addresses physical symptoms and emotional, social and spiritual needs; asking for it does not mean you have abandoned treatment. Supportive care.
Animal and laboratory evidence
Cell, viral and animal experiments can investigate mechanisms or suggest a treatment candidate. They cannot establish an individual’s diagnosis, dose, safety or survival benefit. No preclinical finding is used here as a human efficacy recommendation.
The independent verdict also excludes manufacturer-supported clinical outcomes reviewed for funding or regulatory context. A negative verdict on independence is not a claim that a licensed treatment has no clinical role.
Funding and source roles
Research funding at a glance
51 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI professional MCC PDQ | Khan has consulting and manufacturer-backed research connections; PDQ payments unclosed. | United States | Tier 3 — connected reviewer | C provisional. Updated 9 May 2025; context, not guideline or cleared comparative outcomes. |
| NCI patient MCC PDQ | Professional-PDQ derivation preserves connected provenance; page payments unclosed. | United States | Tier 3 — connected derivation | C provisional. Updated 16 May 2025; context, not cleared efficacy. |
| ESMO–EURACAN MCC guideline, 2024 | No external preparation funding declared; ESMO production/editing. Author company ties. | Lead Warsaw, Poland; international authors | Tier 3 — connected authors | C provisional. DOI 10.1016/j.esmoop.2024.102977; clinical context, not independently cleared outcomes. |
| CAP MCC protocol 4.2 | Exact protocol allocation and current panel payments unclosed; dated Nagarajan declaration cannot clear the 2026 panel. | United States | Tier 3 — fee-supported institution | C provisional. April 2026 release; required January 2027. Pathology reporting scope, not a treatment or screening rule. |
| NCI MCC dictionary definition | Entry, contributor and underlying-source payments unclosed. | United States | Tier 2 — public clinical context | C provisional. Entry revision date not displayed; terminology and risk context only, not efficacy. |
| NCI sentinel-node biopsy | Page, contributor and underlying-study financial chains unclosed. | United States | Tier 2 — public clinical context | C provisional. Reviewed 25 June 2019; procedure and harms only. Breast/melanoma trial findings are not transferred to MCC. |
| NCI radiation therapy | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Updated 15 May 2025; patient education, not independently cleared MCC outcomes. |
| NCI cancer surgery | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Reviewed 8 November 2024; patient education, not independently cleared MCC outcomes. |
| NCI chemotherapy | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Reviewed 15 May 2025; patient education, not independently cleared MCC outcomes. |
| NCI immunotherapy side effects | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Reviewed 16 February 2023; patient education, not independently cleared MCC outcomes. |
| NCI organ inflammation | Page and contributor payments unclosed. | United States | Tier 2 — public safety context | C provisional. Posted 14 June 2019; symptom education, not a home steroid protocol. |
| NCI radiation side effects | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Reviewed 15 May 2025; patient education, not independently cleared MCC outcomes. |
| NCI skin and nail changes | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Reviewed 29 December 2022; patient education, not independently cleared MCC outcomes. |
| NCI infection during treatment | Page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public safety context | C provisional. Reviewed 23 January 2020; urgent infection care, not an antibiotic regimen. |
| NCI lymphedema | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Updated 6 March 2024; patient education, not independently cleared MCC outcomes. |
| NCI nutrition during cancer | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Posted 15 October 2024; patient education, not independently cleared MCC outcomes. |
| NCI sunlight risk | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Reviewed 26 April 2023; patient education, not independently cleared MCC outcomes. |
| NCI complementary medicine | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Updated 31 October 2024; patient education, not independently cleared MCC outcomes. |
| NCCIH cancer complementary approaches | Acknowledged 2021 NCI/NCCIH reviewers; current personal and page payments unclosed. | United States | Tier 2 — public safety context | C provisional. Updated October 2021; safety and nonreplacement context, not independent MCC supplement efficacy. |
| NCI follow-up care | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Updated 2 December 2024; patient education, not independently cleared MCC outcomes. |
| NCI palliative care | Specific page, contributors and underlying studies remain financially unclosed. | United States | Tier 2 — public clinical context | C provisional. Reviewed 1 November 2021; support alongside cancer treatment, not an MCC survival claim. |
| NCI clinical-trial explanation | Specific page, contributor and underlying-study payments unclosed. | United States | Tier 2 — public clinical context | B provisional. Updated 3 November 2024; patient education, not independently cleared MCC outcomes. |
| FDA MCC traditional-approval letter | Regulatory decision; agency has industry-fee and public-budget routes. Trial independence is not established by approval. | Silver Spring, Maryland, United States | Tier 3 — industry-fee regulator | C provisional. Signed 17 December 2025; conversion status only, no independently ranked efficacy. |
| MHRA retifanlimab decision | Regulatory decision; exact product fees and private interests unclosed. | United Kingdom | Tier 3 — industry-fee regulator | C provisional. 6 July 2026 UK first-line adult advanced indication; not worldwide approval or reimbursement. |
| Zynyz US prescribing information | Incyte-produced label. Drug rights, corporate revenues and dated shareholders are separately profiled. | United States | Tier 4 — self-interested producer | D self-interest. Revised May 2026; archive posting 13 July 2026. Regulatory safety role; sponsor efficacy excluded. |
| POD1UM-201 protocol | Incyte sponsor; investigator disclosure forms required but individual receipts not published here. | Wilmington, Delaware, United States | Tier 4 — manufacturer-funded research | D self-interest. Version 7, 16 December 2021; selected sponsor/publication sections, not complete methods or outcomes. |
| Incyte 2025 Form 10-K | Publicly traded producer: product, royalty and contract revenue. MacroGenics licensed worldwide retifanlimab rights; royalty interests have changed. | Wilmington, Delaware, United States | Tier 4 — corporate self-report | D self-interest. Selected business/revenue/license notes; not all accounts or current beneficial owners cleared. |
| Incyte 2026 proxy | Dated table identifies Baker-affiliated funds and other institutional holders; overlapping reports must not be added. | United States | Tier 4 — corporate self-report | D self-interest. 14 April 2026 table has reporting qualifications; current complete cap table and private beneficiaries unclosed. |
| MacroGenics May 2026 Form 8-K | 1 May amendment expands capped Zynyz royalties to a Sagard affiliate; other MacroGenics economic interests retained. | Rockville, Maryland, United States | Tier 4 — interested corporate filing | D self-interest. Actual agreement summary; royalty receipt ledger and complete private-fund beneficiaries unclosed. |
| Sagard website legal identity | Sagard Holdings Management Inc. operates the site; corporate business identity is distinct from a fund’s limited partners. | Toronto, Ontario, Canada | Tier 4 — investor self-report | D self-interest. Actual legal body; no specific healthcare-fund capital ledger or clinical funding cleared. |
| Power 2025 report overview | Reports 31 December 2025 SHMI holdings: Power, Great-West Lifeco and GBL; does not identify every healthcare-fund investor. | Canada | Tier 4 — investor self-report | D self-interest. Selected ownership table/notes; management-company stake is not ownership of every fund asset. |
| NCI budget index | Congressional appropriations through NIH/HHS; enacted allocations and future requests are distinct. | United States | Tier 3 — institutional financial self-report | B provisional. Actual May 2026 index; specific disease-page and contributor allocations unclosed. |
| NCI contributions policy | Gift Fund accepts donations; permitted gifts do not establish a named page donor. | Bethesda, Maryland, United States | Tier 3 — institutional financial self-report | B provisional. August 2025 policy; actual donor receipts and specific page allocations unclosed. |
| NCI PDQ board process | Nongovernment board service can receive honoraria/travel; declared conflicts and recusal are process safeguards. | United States | Tier 3 — institutional process self-report | B provisional. 1 November 2022; process does not clear current private contracts or underlying trials. |
| Khan 2026 published declaration | Khan declares consulting for Delcath, IDEAYA, Immunocore, Regeneron and Replimune. Amounts and PDQ payments unclosed. | New York, United States | Tier 3 — connected-author declaration | C provisional. Published 29 April 2026; actual disclosure/affiliations read, subscription clinical review not adopted. |
| Khan 2023 research protocol | Khan named principal investigator; Pfizer and philanthropy fund the uveal-melanoma project. Personal and PDQ payments not inferred. | Columbia, New York, United States | Tier 4 — manufacturer-funded project | D self-interest. 25 January 2023 cover/identity/funding read; philanthropic donors and full study methods unclosed. |
| Northwell Khan identity profile | Provider-produced nomination identifies Columbia-to-Northwell move; page and personal allocations unclosed. | New York, United States | Tier 3 — provider identity self-report | C provisional. Identity corroboration only; promotional descriptions are not evidence of clinical accuracy. |
| Nature operator terms | Site operator Springer Nature Limited, England; separate group revenues and ownership are profiled. | London, United Kingdom | Tier 4 — commercial publisher self-report | D self-interest. Actual terms body accessed through cookie redirect; not article-specific receipts or editor clearance. |
| Springer Nature 2025 annual report | Subscriptions, publication charges and services; dated group ownership includes Holtzbrinck and a BC Partners-linked vehicle. | Berlin, Germany | Tier 4 — publisher financial self-report | D self-interest. Selected business/ownership notes; 31 December 2025, not current complete private-owner clearance. |
| ESMO 2023 annual report | Meeting, education, membership, grant and investment routes; named pharmaceutical supporters. | Switzerland | Tier 3 — institutional financial self-report | B provisional. Income May 2022–April 2023; supporter period differs. Current ledger and guideline allocations unclosed. |
| ESMO current institutional footer | Swiss registered nonprofit; site funding identified as ESMO. This is not the guideline’s financial clearance. | Lugano, Switzerland | Tier 3 — institutional identity self-report | B provisional. Actual footer and address; no present donor or author-payment ledger. |
| CAP 2025 annual-report finance | Selected table and narrative: testing/accreditation, publications/education, membership/investments, sponsorship and advertising routes. | United States | Tier 3 — institutional financial self-report | B provisional. Specific 2026 protocol funding and current panel payments unclosed; not complete audited-account clearance. |
| CAP contact identity | Organization’s own contact page; no protocol allocation or author contracts disclosed. | Northfield, Illinois, United States | Tier 3 — institutional identity self-report | B provisional. Actual 325 Waukegan Road address; identity only, not independence. |
| Nagarajan February 2022 CME declaration | Nagarajan reports nothing to disclose for this activity; it reports no commercial support. Other faculty declarations are separate. | Texas, United States | Tier 3 — activity disclosure self-report | C provisional. 12 February 2022; cannot clear the 2026 CAP panel, current receipts or provider-wide accounts. |
| FDA FY2026 operating plan | Public budget authority plus regulated-product user fees, including prescription-drug and biologics routes. | United States | Tier 3 — institutional financial self-report | B provisional. Actual selected operating rows; no product-level fee, decision-maker or trial-finance clearance. |
| MHRA 2025–26 accounts | DHSC grant-in-aid, statutory industry fees and service/research income are distinct. | London, United Kingdom | Tier 3 — institutional financial self-report | B provisional. Retained original selected finance passages reread; fresh direct web access failed. No product allocation cleared. |
| NCCIH appropriations history | Federal appropriations history; the displayed series ends in 2024. | United States | Tier 3 — institutional financial self-report | B provisional. No inferred FY2026 amount, disease-page allocation or original-trial independence. |
| NCCIH donation policy | Conditional and unconditional donations permitted; actual named cancer-page gifts unclosed. | Bethesda, Maryland, United States | Tier 3 — institutional financial self-report | B provisional. Donation authority is not evidence a particular donor paid a page or reviewer. |
| NHS sepsis emergency advice | Specific page, contributor and underlying-source allocations unclosed. | United Kingdom | Tier 2 — public safety context | B provisional. Reviewed 14 May 2026; UK emergency instructions translated to local emergency services. |
| NHS breathlessness emergency advice | Specific page and contributor allocations unclosed. | United Kingdom | Tier 2 — public safety context | B provisional. Reviewed 30 January 2024; no symptom list can exclude an emergency. |
| NHS national content policy | DHSC-funded site; states no advertising or corporate sponsorship. Individual-source payments remain unclosed. | United Kingdom | Tier 3 — institutional process self-report | B provisional. October 2022; October 2025 review deadline passed. Does not establish provider finances or trial independence. |
Frequently asked questions
Does MCC always hurt? No. Painless lesions still need assessment. Presentation.
Does a virus test diagnose MCC? No; tissue assessment is required. Biology.
Does a negative sentinel-node biopsy rule out all spread? No. False-negative results occur; interpret pathology with the whole assessment. Limitations.
Can supplements replace cancer treatment? No. Do not delay care for supplements or black salves. Safety.
Is all treatment the same worldwide? No. Product indications, access and individual suitability differ; verify the local plan with the team. Dated UK authorization.
Sources and funding notes
Financial profiles identify documented routes and unresolved allocations.
Mirror read; canonical PMC access failed.
Long financial reports were read selectively; whole accounts and private contracts remain unclosed.
Approval dates, label revisions and repository postings differ.
Whole-source accounting includes full clinical and financial units, metadata, headings and repeated facts.
- NCI professional MCC PDQ — Definition, biology and professional-reviewer identification.
- NCI patient MCC PDQ — Presentation, staging and treatment-setting context.
- ESMO guideline.
- CAP MCC protocol 4.2 — Selected cover, reporting fields, AJCC 8 and viral-testing sections.
- NCI MCC dictionary definition — Skin location, older age and weakened-immune-system context.
- NCI sentinel-node biopsy — Node procedure, false negatives and complications.
- NCI radiation therapy — Local external-beam treatment and planning context.
- NCI cancer surgery — Surgical risks, preparation and discharge care.
- NCI chemotherapy — Systemic treatment, healthy-cell effects and response assessment.
- NCI immunotherapy side effects — Reactions can occur during or after treatment.
- NCI organ inflammation — Selected organ-warning and emergency-information passages.
- NCI radiation side effects — Field-dependent and delayed adverse effects.
- NCI skin and nail changes — Treatment-field skin care and severe rash warnings.
- NCI infection during treatment — Immediate oncology contact for fever/infection and antipyretic masking.
- NCI lymphedema — Swelling assessment, trained therapy and cellulitis urgency.
- NCI nutrition during cancer — Nutrition assessment and dietitian support.
- NCI sunlight risk — UV protection; no claim it treats established MCC.
- NCI complementary medicine — Herbal/supplement reconciliation and treatment-interference limits.
- NCCIH cancer complementary approaches — No replacement/delay; black-salve hazards and uncertain antioxidant interference.
- NCI follow-up care — Individual care summaries, coordination and survivorship planning.
- NCI palliative care — Physical, emotional, social and spiritual support.
- NCI clinical-trial explanation — Research purposes and distinction from established care.
- FDA MCC traditional-approval letter — MCC accelerated-to-traditional US approval conversion.
- MHRA retifanlimab decision — Jurisdiction-specific authorization, not trial outcome ranking.
- Zynyz US prescribing information — Selected indication, warnings, reproduction and medication-guide passages.
- POD1UM-201 protocol — Documents sponsorship; efficacy excluded from independent verdict.
- Incyte 2025 Form 10-K — Corporate identity and drug-rights route, distinct from efficacy.
- Incyte 2026 proxy — Selected beneficial-ownership table and notes, not a present ownership guarantee.
- MacroGenics May 2026 Form 8-K — Newer financial route than the 2025 Incyte report.
- Sagard website legal identity — Operator and principal-business location only.
- Power 2025 report overview — Dated Sagard management-company backers, not PDQ or trial payments.
- NCI budget index — Institutional public-finance route, not author/trial clearance.
- NCI contributions policy — Gift authority and institution location only.
- NCI PDQ board process — Editorial process, not a reviewer-specific no-conflict certificate.
- Khan 2026 published declaration — Financial-only uveal-melanoma review disclosure, not MCC efficacy.
- Khan 2023 research protocol — Dated research connection only; outcomes excluded.
- Northwell Khan identity profile — Links the named researcher’s institutional identities; not provider accounts.
- Nature operator terms — Operator identity, not independent clinical evidence.
- Springer Nature 2025 annual report — Publisher funding/ownership route; article-level payments unclosed.
- ESMO 2023 annual report — Selected investment narrative and revenue/supporter pages.
- ESMO current institutional footer — Institution identity/location only.
- CAP 2025 annual-report finance — Actual selected finance table and accompanying narrative.
- CAP contact identity — Institution headquarters/contact location.
- Nagarajan February 2022 CME declaration — Full dated activity declaration, not a present no-conflict claim.
- FDA FY2026 operating plan — Agency financial context only.
- MHRA 2025–26 accounts — Selected institutional funding notes, not all accounts/private interests.
- NCCIH appropriations history — Public funding route, not contemporary complete finances.
- NCCIH donation policy — Gift route and institutional location.
- NHS sepsis emergency advice — Severe infection emergency recognition, not MCC diagnosis.
- NHS breathlessness emergency advice — Immediate help for severe breathing difficulty or related warning signs.
- NHS national content policy — National site policy only.
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.